Who
Erik Harris
EVP & Chief Commercial Officer
Company insider
Files Form 4 as: EVP & Chief Commercial Officer, Ultragenyx Pharmaceutical; Director, Rezolute; Director, Inozyme Pharma; Director, Denali Therapeutics.
In numbers
- Trades disclosed
- 62
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $2.9M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 19 Jun 2019
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —28,895 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —49,960 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —49,960 at $0.00 | filing |
| 16 Apr 2026filed 20 Apr 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —28,895 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $240K10,539 at $22.80 | filing |
| 2 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $240K10,539 at $22.80 | filing |
| 1 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —11,643 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —11,643 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 25 Mar 2025filed 26 Mar 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 3 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Sold | $636K15,103 at $42.10 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —30,246 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —16,813 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —18,443 at $0.00 | filing |
| 3 Oct 2024filed 7 Oct 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,901 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,967 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —34,200 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | RARE Ultragenyx PharmaceuticalBiotechnology | SEC FORM 4 Code A | —19,400 at $0.00 | filing |
News
Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)RARE · themarketsdaily.com · 15 Oct 2026Ultragenyx (NASDAQ: RARE) agrees to sell PRV for $203 million in cashRARE · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Erik Harris; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.